Edward Kaye, M.D., currently serves on the boards of directors at Stoke Therapeutics, Cytokinetics, Inc., and the Massachusetts Biotechnology Council. Dr. Kay previously served as CEO of Stoke Therapeutics. Prior to that, Dr. Kaye served as CEO and a director of Sarepta Therapeutics, where he led the successful effort to win FDA approval of Exondys 51, a pioneering drug for Duchenne Muscular Dystrophy. Before becoming CEO at Sarepta, he served as the company’s Chief Medical Officer for six years, leading the development of Exondys 51. Earlier in his career, Dr. Kaye spent 10 years at Genzyme Corporation, most recently as Group Vice President of Clinical Development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. Prior to entering the biotech industry, Dr. Kaye trained in pediatrics, pediatric neurology and biochemical genetics. He was a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center, and served as chief of biochemical genetics at the Children’s Hospital of Philadelphia. He remains on the pediatric neurology staff at Boston Children’s Hospital. Dr. Kaye earned his B.S. in biology/chemistry from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.